Ballenberger, Freytag, Wenisch
- Address
- Robert-Koch-Strasse 1, 63263 Neu-Isenburg, Germany
Ballenberger, Freytag, Wenisch - Respiratory Allergy and Asthma Research
This clinical research center specializes in advanced therapeutic interventions for respiratory allergic conditions and severe asthma. The facility focuses on evaluating novel biological therapies and immunotherapy approaches for patients with complex allergic and eosinophilic airway diseases, conducting both long-term safety studies and efficacy trials for innovative treatment modalities.
- Severe eosinophilic asthma management and biological therapy assessment
- House dust mite (HDM) allergy and allergic rhinoconjunctivitis treatment
- Subcutaneous immunotherapy (SCIT) clinical trials
The center's research portfolio includes investigation of depemokimab for severe asthma with eosinophilic phenotype, focusing on long-term safety profiles in open-label extension studies. Additionally, the team evaluates subcutaneous immunotherapy efficacy for patients suffering from moderate to severe allergic rhinitis and rhinoconjunctivitis induced by house dust mite allergy, with or without concomitant asthma, utilizing comprehensive clinical outcome measures including the Total Combined Rhinitis Score.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 60 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 60 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ballenberger, Freytag, Wenisch
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Jul 2023 | Jul 2025 |
IMP list
lock Showing 1 of 60 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluticasone Propionate | 3 | Unknown | 2024-06-04 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.